BR112018012915A2 - co-cristal, método de produção do mesmo, e medicamento contendo co-cristal - Google Patents

co-cristal, método de produção do mesmo, e medicamento contendo co-cristal

Info

Publication number
BR112018012915A2
BR112018012915A2 BR112018012915A BR112018012915A BR112018012915A2 BR 112018012915 A2 BR112018012915 A2 BR 112018012915A2 BR 112018012915 A BR112018012915 A BR 112018012915A BR 112018012915 A BR112018012915 A BR 112018012915A BR 112018012915 A2 BR112018012915 A2 BR 112018012915A2
Authority
BR
Brazil
Prior art keywords
acid
crystal
production
medicament containing
crystals
Prior art date
Application number
BR112018012915A
Other languages
English (en)
Other versions
BR112018012915B1 (pt
Inventor
Iwata Kentaro
Kimoto Koya
Kitayama Masato
Yamamoto Mitsuo
Hohokabe Miyuki
Sawai Yasuhiro
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112018012915A2 publication Critical patent/BR112018012915A2/pt
Publication of BR112018012915B1 publication Critical patent/BR112018012915B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C07C59/50—Mandelic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10—Salicylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se a um co-cristal de (s) -3- (1-((1-acriloilpirrolidin-3-il)óxi) isoquinolin-3-il)-1h-1,2,4-triazol-5(4h)- ona e um ácido orgânico capaz de formar um co-cristal com o composto. os co-cristais específicos preparados são co-cristais com ácido gentísico, ácido salicílico, ácido maleico, ácido malônico, ácido málico, ácido mandélico e ácido cítrico.
BR112018012915-1A 2015-12-24 2016-12-22 Co-cristal, método de produção do mesmo, e medicamento contendo co-cristal BR112018012915B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-252658 2015-12-24
JP2015252658 2015-12-24
PCT/JP2016/089224 WO2017111179A1 (en) 2015-12-24 2016-12-22 Cocrystal, production method thereof, and medicament containing cocrystal

Publications (2)

Publication Number Publication Date
BR112018012915A2 true BR112018012915A2 (pt) 2018-12-11
BR112018012915B1 BR112018012915B1 (pt) 2023-09-19

Family

ID=

Also Published As

Publication number Publication date
IL260195A (en) 2018-07-31
JP2019504025A (ja) 2019-02-14
TN2018000221A1 (en) 2019-10-04
KR20180095933A (ko) 2018-08-28
PL3394045T3 (pl) 2021-09-27
TWI722080B (zh) 2021-03-21
AU2016375899B2 (en) 2021-05-13
CO2018006473A2 (es) 2018-07-10
AU2016375899A1 (en) 2018-07-19
PH12018501356A1 (en) 2019-02-18
AR107132A1 (es) 2018-03-21
US20170183326A1 (en) 2017-06-29
CN108473467B (zh) 2021-08-13
SG11201805331QA (en) 2018-07-30
ZA201804393B (en) 2019-09-25
UY37046A (es) 2017-07-31
DK3394045T3 (da) 2021-08-16
JP6876704B2 (ja) 2021-05-26
ECSP18055921A (es) 2018-10-31
CL2018001725A1 (es) 2018-10-19
EA039213B1 (ru) 2021-12-17
TW201730181A (zh) 2017-09-01
US10836745B2 (en) 2020-11-17
WO2017111179A1 (en) 2017-06-29
EP3394045A1 (en) 2018-10-31
ES2877089T3 (es) 2021-11-16
HK1256362A1 (zh) 2019-09-20
MX2018007721A (es) 2018-08-15
CN108473467A (zh) 2018-08-31
EA201891467A1 (ru) 2018-12-28
CA3009610A1 (en) 2017-06-29
CA3009610C (en) 2024-02-13
EP3394045B1 (en) 2021-05-19

Similar Documents

Publication Publication Date Title
BR112016014018B8 (pt) Processo para a preparação dos compostos de cetona (ia), e processo para a preparação dos compostos de triazol de fórmula (ic)
PH12018501356A1 (en) Cocrystal, production method tereof, and medicament containing cocrystal
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
PE20161022A1 (es) Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5´-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteinas quinasa dependientes de adn
EA201691881A1 (ru) Новые соединения
AR100818A1 (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
PH12018500377A1 (en) Novel annelated benzamides
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
BR112014018909A8 (pt) Compostos, processo para a preparação dos compostos, composição agroquímica, método para o combate dos fungos, utilização dos compostos e semente
EA201691878A1 (ru) ИНГИБИТОРЫ СИГНАЛЬНЫХ ПУТЕЙ Wnt
MA41975B1 (fr) Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer
CO2017008721A2 (es) Compuestos derivados de n-[[1,3,4-oxadiazol-2-il]tetrahidropiran-4-il]-n-metilbenzamida o n-[[1,2,4-triazol-3-il]tetrahidro-2h-piran-4-il]-n-metilbenzamida activos como agonistas de gpr142, composiciones que los comprenden y proceso para la producción de los mismos
CR20170261A (es) Ácido 3-(6-alcoxi-5-clorbenzo[d]isoxazol-3-il)propanoico útil como inhubidores de quinurenina monooxigenasa
EA201792502A1 (ru) Кабазитаксел и его применение для лечения рака
EA202191161A1 (ru) Новый способ получения (s)-2-(2-(4-гидроксифенил)ацетамидо)-3-фенилпропановой кислоты
TH181906A (th) อินดาโซลที่ถูกแทนที่ชนิดใหม่, กระบวนการสำหรับการจัดเตรียมพวกมัน, สารจัดเตรียมเชิงเภสัชกรรม ซึ่งประกอบรวมด้วยพวกมัน และการใช้งาน ของพวกมันสำหรับการผลิตเวชภัณฑ์ยา
ZA202201221B (en) Cyclopentane compounds
TH168843A (th) กระบวนการเตรียมสารยับยั้ง jak1 และรูปแบบใหม่ของสารยับยั้งดังกล่าว
TH167246A (th) สารประกอบไบแอริลเอไมด์ เป็นสารยับยั้งไคเนส
TH182770A (th) ตัวยับยั้งแอลโดสเทอโรน ซินเธส
UA113479C2 (xx) Динатрієва сіль 2-(2-метил-5,8-диметоксихінолін-4-ілтіо)сукцинатної кислоти, що проявляє антиоксидантну та нейропротекторну активності
TH1701003364A (th) กรด 3-(6-แอลคอกซี-5-คลอโรเบนโซ[d]ไอซอกซาโซล-3-อิล) โพรพาโนอิกที่มีประโยชน์ในฐานะสารยับยั้งไคนูเรนีนโมโนออกซีจีเนส
TH171926A (th) ไพราโซโล-ไพริดีนามีนที่ถูกแทนที่ (substituted pyrazolo-pyridinamines)
UA112146C2 (uk) Спосіб отримання 4,1-бензоксатієпін-3-ону

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2016, OBSERVADAS AS CONDICOES LEGAIS